Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

555
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
555
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

5.1K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.1K
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

824
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
824
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.1K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

47
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
47
Cancer Vaccines01:30

Cancer Vaccines

400
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
400

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autophagy modulation in cancer.

Nature reviews. Drug discovery·2026
Same author

Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-Seq.

Nature communications·2026
Same author

NKG2A inhibition promotes NK cell-CD8<sup>+</sup> T cell interactions to improve anticancer immunity in ovarian carcinoma.

Nature communications·2026
Same author

Ovarian cancer metastasis to the human omentum disrupts organ homeostasis and induces fundamental tissue reprogramming.

Nature communications·2025
Same author

Context-dependent impact of type I interferon signaling in cancer.

Molecular cancer·2025
Same author

Partial mitochondrial involvement in the antiproliferative and immunostimulatory effects of PT-112.

Oncoimmunology·2025
Same journal

Diversity, Equality, and Inclusion in the naïve T Cell Receptor Repertoire.

Immunological reviews·2026
Same journal

Macrophage Plasticity and Immune Remodeling in Ischemic Heart Failure.

Immunological reviews·2026
Same journal

The T Cell Receptor: Molecular Sensor, Therapeutic Mediator and Probabilistic Driver of Adaptive Immunity.

Immunological reviews·2026
Same journal

Tissue-Resident Memory T Cells in the Heart: An Emerging Role in Chronic Inflammation.

Immunological reviews·2026
Same journal

Rethinking Immunity in Tissues: The Biology of Tertiary Lymphoid Structures.

Immunological reviews·2026
Same journal

Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.

Immunological reviews·2026
See all related articles

Related Experiment Video

Updated: Jul 17, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K

Type I interferon and cancer.

Peter Holicek1,2, Emma Guilbaud3, Vanessa Klapp4,5

  • 1Sotio Biotech, Prague, Czech Republic.

Immunological Reviews
|September 5, 2023
PubMed
Summary
This summary is machine-generated.

Type I interferon (IFN) has a dual role in cancer. Robust IFN responses fight cancer, while weak responses promote tumor growth and therapy resistance, impacting malignant transformation and treatment outcomes.

Keywords:
CGASSTING1apoptotic cell deathimmunogenic cell deathinterferon-stimulated genespattern recognition receptors

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-&#945;
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Related Experiment Videos

Last Updated: Jul 17, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-&#945;
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.0K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Type I interferons (IFN) are key cytokines with complex roles in cancer.
  • Their signaling influences malignant transformation, tumor progression, and therapeutic responses.
  • Context-dependent effects range from anticancer immunity to tumor promotion.

Purpose of the Study:

  • To review the multifaceted roles of type I IFN signaling in cancer.
  • To elucidate the mechanisms behind both anti- and pro-tumorigenic effects of type I IFN.
  • To discuss the implications for cancer therapy and treatment strategies.

Main Methods:

  • Literature review of fundamental aspects of type I IFN signaling.
  • Analysis of context-dependent impacts on malignant transformation, tumor progression, and therapy response.
  • Synthesis of information on both beneficial and detrimental roles of type I IFN.

Main Results:

  • Robust, acute type I IFN responses exhibit anticancer effects via direct cytotoxicity and immunostimulation.
  • Type I IFN signaling is crucial for the efficacy of immunogenic therapeutics like ICD inducers and ICIs.
  • Weak, non-resolving type I IFN responses promote tumor progression, therapy resistance, stemness, and immune exhaustion.

Conclusions:

  • Type I IFN signaling presents a double-edged sword in oncology.
  • Understanding the context-specific functions of type I IFN is critical for optimizing cancer treatments.
  • Targeting or modulating type I IFN pathways may offer novel therapeutic strategies.